Mina Thabet Kelleni

Learn More
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury worldwide. It covers a wide spectrum of hepatic disorders ranging from simple steatosis, through steatohepatitis (steatosis with inflammation), to cirrhosis. The molecular and cellular mechanisms underlying hepatic injury in NAFLD are not clear. Several evidences(More)
Doxorubicin (DOX) is a widely used antineoplastic drug whose efficacy is limited by its cardiotoxicity. The aim of this study was to investigate the possible protective role of the antidiabetic drugs metformin (250 mg/kg dissolved in DW p.o. for seven days) and sitagliptin (10 mg/kg dissolved in DW p.o. for seven days) in a model of DOX-induced (single dose(More)
Editorial In the past few years, rituximab has been recognized as a safe and effective emerging treatment for autoimmune hemolytic anemia (AIHA) [1,2]. Rituximab was also considered as a preferred second-line therapy of warm antibody hemolytic anemia in adults in some major European centers and it was shown that second-line treatment with rituximab led to(More)
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury; however its therapeutic strategy has not been established yet. Nitro-aspirin (NO-aspirin) is a new molecule in which aspirin and a NO-donating group are covalently linked. This study investigated the potential protective effect of NO-aspirin on NAFLD. Experimental(More)
Type 2 diabetes (T2D) is a growing public health concern that accounts for approximately 90% of all the cases of diabetes. Besides insulin resistance, T2D is characterized by a deficit in beta-cell mass. Increasing evidence points to the cytotoxicity of islet amyloid polypeptide (IAPP) aggregates showing them not just an insignificant phenomenon derived(More)
Hepatitis C virus (HCV) is the leading cause of chronic liver disease, including cirrhosis and cancer, and liver transplantation. Undoubtedly, effective antiviral therapy is highly essential for achieving sustained virological response (SVR) in HCV-infected patients [1,2]. Simeprevir (SMV) is a macrocyclic NS3/4A HCV protease inhibitor with a potent(More)
Methotrexate (MTX) is a commonly used antineoplastic and anti-rheumatoid drug whose efficacy is limited by its hepatotoxicity. The aim of this study was to investigate the possible protective role of captopril (100 mg/kg/day, p.o. for seven days), an angiotensin converting enzyme inhibitor, and telmisartan (10 mg/kg/day p.o. for seven days), an angiotensin(More)
  • 1